OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Anavex Life Sciences Corp. ("Anavex") (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS), and various types of cancer, has qualified to trade on OTCQX®, the best marketplace for established, global and growth companies.
Anavex begins trading today on OTCQX under the symbol "AVXL." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"We are pleased to welcome Anavex to the OTCQX marketplace," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "Growing U.S. companies like Anavex choose OTCQX to demonstrate transparency and increase their visibility and engagement with U.S. investors. We look forward to working with Anavex's management team as the company continues to grow and expand its presence in the U.S. market."
"We are pleased that Anavex has been approved for trading on the OTCQX marketplace," said Christopher U. Missling, PhD, President and Chief Executive Officer for Anavex. "Together with our development milestones, such as the recent commencement of a Phase 2a trial for our Alzheimer's compound ANAVEX 2-73 and drug combination ANAVEX PLUS, the increased visibility and transparency of the OTCQX marketplace has the potential to help increase the liquidity for our stock and improve shareholder value over the long term."
K&L Gates LLP serves as Anavex's Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws.
Liver cells effectively serve as immune checkpoint regulating anti-cancer immunity